Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02689284
Title Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors MacroGenics

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma


Margetuximab-cmkb + Pembrolizumab

Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.